OLEMA PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
OLEMA PHARMACEUTICALS, INC. (OLMA) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price of $9.87 per share as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice · last filed 2026-08-10
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $9.87.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $10.08.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $10.36.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $9.99.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $9.87 10-Q · filed 2026-08-10 |
| 2026-03-31 | $10.08 10-Q · filed 2026-05-12 |
| 2025-12-31 | $10.36 10-K · filed 2026-03-16 |
| 2025-09-30 | $9.99 10-Q · filed 2025-11-10 |
| 2025-06-30 | $10.01 10-Q · filed 2025-08-11 |
| 2025-03-31 | $9.94 10-Q · filed 2025-05-13 |
| 2024-12-31 | $9.41 10-K · filed 2025-03-18 |
| 2024-09-30 | $9.04 10-Q · filed 2024-11-12 |
| 2024-06-30 | $9.39 10-Q · filed 2024-08-06 |
| 2024-03-31 | $9.50 10-Q · filed 2024-05-08 |
| 2023-12-31 | $9.88 10-K · filed 2024-03-11 |
| 2023-09-30 | $9.91 10-Q · filed 2023-11-07 |
| 2023-06-30 | $10.05 10-Q · filed 2023-08-08 |
| 2023-03-31 | $9.70 10-Q · filed 2023-05-09 |
| 2022-12-31 | $10.21 10-K · filed 2023-03-09 |
| 2022-09-30 | $14.20 10-Q · filed 2022-11-08 |
| 2022-06-30 | $14.01 10-Q · filed 2022-08-09 |
| 2022-03-31 | $13.44 10-Q · filed 2022-05-09 |
| 2021-12-31 | $11.33 10-K · filed 2022-02-28 |
| 2021-09-30 | $7.38 10-Q · filed 2021-11-10 |
| 2021-06-30 | $7.24 10-Q · filed 2021-08-10 |
| 2021-03-31 | $5.94 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |